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1) We aimed to (i) identify the differences in baseline clinical and magnetic resonance imaging 
(MRI) features associated with conversion to a neurodegenerative disease in the following four 
years; (ii) validate, based on these data, some easy-to-use clinical and MRI criteria that could help 
to identify, at the individual level, those MBI subjects at higher risk to receive a clinical diagnosis 
of dementia over time. 
2) We found that the presence of an executive deficit, severe theory of mind impairment and the 
presence of isolated frontal atrophy (i.e. with a spared volume within the remaining cortical regions) 
were associated with a higher risk of progression from MBI to a clinically evident 
neurodegenerative condition over the following 4 years. 
3) Our results suggest that identifying MBI in the general population would help identify patients 




Objective: As an analogy with mild cognitive impairment (MCI), the mild behavioural impairment 
(MBI) construct has been proposed as a diagnostic label for those presenting late-onset behavioural 
symptoms. To date, however, the clinical, cognitive and structural imaging features associated with 
an increased risk of conversion from MBI to dementia are poorly understood.  
Methods: We retrospectively analysed the cognitive performance and structural brain MRI of 113 
subjects, with a clinical follow-up of at least 4 years available. Subjects were randomly assigned to 
a Group A (56 subjects; age: 65.4±7.9 years, 15 females, MMSE score: 28.4±2.3)) or to a Group B 
(57  subjects, age: 66.6±6.4, 17 females, MMSE score: 28.0±1.4). In the Group A, cognitive and 
structural variables were compared between converters (at 4 years) and non-converters and then 
verified in the Group B group.  
Results: In the Group A, 14 patients converted to bv-FTD and 4 to Alzheimer‟s Disease (AD). 
Converters presented at baseline lower executive function scores and total Theory of Mind (ToM 
scores), as well as more severe focal frontal atrophy. In the Group B, 13 subjects converted to bv-
FTD and none to AD. The combination of the variables identified in the Group A significantly 
(p<0.001) discriminated between converters and non-converters in the Group B with a sensitivity of 
0.615 and a specificity of 1 (total accuracy 91.22%). 
Conclusion: The combined presence of executive deficit, impaired ToM, and presence of isolated 
frontal atrophy was associated with risk of progression from MBI to a clinically evident 
neurodegenerative condition, mainly bv-FTD, over a 4-year period.  
 
  
         
Introduction 
 
Recent years have seen an increasing interest of the clinical community for newly developed 
behavioural symptoms as a possible early manifestation of neurodegenerative disease, mainly the 
behavioural-variant of frontotemporal dementia (bv-FTD)
1
, but also Progressive Supranuclear Palsy 
(PSP), Alzheimer‟s disease (AD), and dementia with Lewy bodies (DLB)
2
. 
The observation of a possible role for behavioural symptoms as an early “red flag” for the 
development of a brain neurodegenerative disease led to the development of a new diagnostic 
entity, i.e. mild behavioural impairment (MBI), mirroring the successful mild cognitive impairment 
(MCI) construct.  
Tarangano and colleagues (2003)
3
 defined the MBI syndrome as consisting of persistent newly 
developed behavioural changes and mild neuropsychiatric symptoms, no serious cognitive 
complaint and normal activities of daily living (summarized in Table 1). The presence of MBI has 
been associated with an increased risk of progression to dementia
2,4–7
.  
Like MCI, that has an annual conversion rate to AD dementia of 31% 
8
, MBI is a heterogeneous 
condition, which includes late-onset psychiatric disorders (i.e. the development in late adulthood of 
primary psychiatric disorders in subjects with a negative psychiatric history) chronic 
cerebrovascular damage and neurodegenerative diseases. To increase the clinical relevance of MBI, 
it is needed to identify those features that characterize the presence of a subclinical 
neurodegenerative process as the underlying cause of MBI.  
Here, focusing on a naturalistic cohort presenting to a behavioural neurology/adult psychiatric 
service for the onset of newly developed and progressive social difficulties, we aimed to 1) identify 
the differences in baseline clinical and magnetic resonance imaging (MRI) features associated with 
conversion to a neurodegenerative disease in the following four years; 2) validate, based on these 
data, some easy-to-use clinical and MRI criteria that could help to identify, at the individual level, 
those MBI subjects at higher risk to receive a clinical diagnosis of dementia over time in an 
independent MBI set.   
 
Materials and Methods 
 
Patients 
Using a retrospective approach, we identified all subjects who came to the attention of our 
behavioural neurology/adult psychiatric services between 2007 and 2014 for the onset of informant-
confirmed, newly-developed and progressive behavioural symptoms who fulfilled the following 
criteria: (i) age between 60 and 75 years, (ii) at least 8 years of formal education, (iii) development 
of new behavioural deficits fulfilling current MBI criteria
1,9
 (such as reduction of empathy, 
emotional callousness, social inappropriate conduct), that were persistent for at least six months, 
evaluated during two clinical assessments separated by at least three months, not attributed by the 
examining neurologist or psychiatrist to a mood disorder, and confirmed by the clinical history 
reported by the informant, (iv) no complaint of cognitive difficulties by the patient or the caregiver, 
(v) no highly stressful event in the previous six months as defined by the score on the Perceived 
Stress Scale (PSS
10
), (vi) lack of a positive history for major depressive disorder, bipolar disorder, 
abuse of psychoactive drugs or any psychotic disorder, recent bereavement, dementing illnesses, or 
for a major medical condition, (vii) no diagnosis of a neurodegenerative condition at the end of the 
         
baseline evaluation, (viii) availability on file of a baseline clinical MRI brain scan and brief 
cognitive assessment (see below for minimum requirements), and (ix) at least 4 years of clinical 
follow-up after the first evaluation. The focus on subjects older than 60 years is based on the work 
on MBI of Tarangano
9
, with the aim reduce the proportion of subjects presenting with a primary 
late-onset psychiatric condition
11,12
 , while the exclusion of subjects more than 75 years of age, was 
based on the need to increase consistency with published theory of mind normative data
13
. We also 
decided to include an education exclusion criteria, given the dependence of some of the included 




Based on these criteria, we retrospectively selected 113 subjects and extracted their baseline 
clinical, cognitive and MRI data, focusing on the variables described below and reviewed the 
available follow-up data collected in the 4 years following the baseline evaluation to assess if any of 
the subjects converted to a neurodegenerative condition according to currently available diagnostic 
criteria. Due to differences in intermediate follow-up intervals, we decided to focus on the baseline 
clinical and MRI data evaluation and only on the clinical outcome 4 years later (i.e. not on the 
intermediate time-points).  
The patients were then randomly divided into two sets: Group A (56 subjects, age: 65.4±7.9, 15 
females, MMSE score: 28.4±2.3) and Group B (57 subjects, age: 66.6±6.4, 17 females, MMSE 
score: 28.0±1.4).  
 
Cognitive and Behavioral assessment 
The cognitive evaluation was based on a brief neuropsychological battery that included tests for the 
assessment of global cognition (MMSE
15
), Theory of Mind (ToM) abilities („„Reading the Mind in 
the Eyes Test‟‟- RMET
13,16
), executive functioning (TMT A and B
17
, letter fluency test
18
), verbal 
(Rey-Auditory Verbal Learning Test
19
) and non-verbal (Rey figure recall
20
) memory, behavioral 
and psychological symptoms (Neuropsychiatric Inventory - NPI
21
). Test scores for the executive 
functions and memory test were converted to z-scores (modified accordingly to represent a worse 
performance with lower z scores) according to normative data and then averaged to provide a 
composite “executive functions” and a composite “memory functions” z score.  
MRI Acquisition 
MRI scans were acquired according to good clinical practice at 1.5 T. given the retrospective, 
clinical, nature of the study, images were acquired on different scanners, however only subjects 
presenting with a volumetric T1 sequence with an isotropic voxel in the 1-1.5 mm range and with 
T2 whole brain images were considered eligible for the study.  
T1-weighted Images were all resliced to an isotropic voxel size of 1.5 mm and then visually 
evaluated using standardized scales for the presence of global cortical atrophy
22
, medial temporal 
lobe (MTL) atrophy
23
 and frontal lobe atrophy based on the composite assessment of orbito-frontal, 
anterior cingulate and frontal-insular regions as previously described
24
. Two separated raters 
evaluated the scans and then a consensus evaluation was reached. The scores were then simplified 
into no relevant atrophy (scores 0-1) or relevant atrophy (scores of 2 or more)
24
 except for the 
Scheltens scale that was simplified as no relevant atrophy (scores 0-2) or relevant atrophy (scores of 
3 or more) as in previous studies
25
. Lastly, the Fazekas scale
26
 was used to evaluate the global 
burden of chronic white matter vascular disease in T2-weighted images.  
         
Statistical analysis 
In the Group A we compared the baseline clinical and MRI features (the cognitive and behavioural 
assessment, the presence of global, medial-temporal and frontal atrophy) between converters to 
dementia and non-converters, using t-tests (for continuous variables) or chi-square statistics (for 
binary variables). All significant results were then confirmed correcting for age, sex, education, 
MMSE and NPI respectively using an ANCOVA and logistic regression.  
We then used the results to suggest imaging and clinical indices that could help identifying those 
MBI subjects more at risk to develop a clinical diagnosis of dementia over time, and then used these 
criteria to predict which patients in the Group B group would develop dementia.   
Based on the results obtained in the Group A we defined the following two indices to be used in the 
Group B (summarized in Table 2): 
- Cognitive and behavioural (Cog-Behav) index, the presence of all of the following: a 
composite executive function z score lower than -1, a RMET score lower than 21 (i.e. the 
accepted cut off for a pathological RMET score
27
) and a composite memory function z score 
higher than -1. 
- MRI index: presence of isolated frontal atrophy (i.e. relevant frontal atrophy with preserved 
volume within the remaining cortical areas). 
We have not included the NPI in these two dimensions as this scale overlaps with the diagnostic 
criteria of MBI and FTD, it does not present with a clear cut-off, and was used as correction 
variable in the statistical analysis. 
These two indices of conversion risk, derived from the Group A, represent easy-to-recognize 
features that could be used by clinicians to identify which MBI patients at baseline are at higher risk 
to conversion to dementia. We used to indices to categorize patients in the Group B.  
Data are reported as mean  standard deviation. P values are reported as uncorrected, as well as 
corrected for multiple comparisons using a false discovery rate approach; lastly we also reported if 
they survived the Bonferroni‟s correction. 
Data reported in the study were acquired during clinical practice in line with the principles of the 




Group A: Baseline demographics, clinical, MRI characteristics and conversion rate 
Demographic and clinical data for the Group A are reported in Table 3. There was no difference in 
age, sex distribution, education and MMSE score between converters and non-converters. 
At 4 years, we observed that 18 patients converted to dementia during the follow-up (14 to bv-
FTD
28
 and 4 to AD
29
 and; the cumulative 4-year conversion rate was thus 18/56 (32,14%). 
As compared to non-converters, converters showed at baseline a lower executive function 
composite and total RMET scores and a higher NPI score. The correlations between the cognitive 
and behavioural metrics are reported in Supplementary Table 1. 
Moreover, compared to non-converters, converters showed a more marked frontal atrophy while 
there was no difference between the two groups in white matter vascular load, MTL atrophy, and 
whole brain atrophy. All these significant statistical findings survived Bonferroni‟s correction for 
multiple comparisons. 
See Table 3 for p-values, t-values and degrees of freedom. 
 
         
Group B: Baseline demographics, clinical, MRI characteristics and conversion rate 
Demographic and clinical data for the Group B are reported in Table 4. 
Thirteen patients converted to dementia in the course of follow-up (all to bv-FTD); the cumulative 
4-year conversion rate was thus 13/57 (22,8%). 
We explored at the single-subject level, the presence and frequency of the Cog-Behav index and 
MRI conversion risk indices obtained in the Group A.  
There was a significant difference between converters (10 out of 13) vs non-converters (3 out of 44) 
in the presence of isolated frontal atrophy. There was also a significant difference between 
converters (9 out of 13) and non-converters (2 out of 44) in the executive function and RMET 
scores. 
Lastly, there was a significant difference between converters (8 out of 13) vs non-converters (0 out 
of 44) for both the MRI and Cog-Behav indices. 
All these significant statistical findings survived Bonferroni‟s correction for multiple comparisons. 
See Table 4 for p-values, t-values and degrees of freedom. 
 
Sensitivity, Specificity and total Accuracy 
Based on the Group B results, we evaluated the sensitivity and specificity of the MRI and the Cog-
Behav conversion risk indices. The MRI index had a sensitivity of 0.769 and a specificity of 0.931 
(total accuracy 89.47%); the Cog-Behav index had a sensitivity of 0.692 and a specificity of 0.954 
(total accuracy 89.47%); the combined presence of the MRI and Cog-Behav criteria had a 
sensitivity of 0.615 and a specificity of 1 (total accuracy 91.22%). Lastly, the sensibility and 
specificity of the single components of the Cog-Behav index are reported in Supplementary Table 
2. 
 
Clinical outcomes of non-converters  
In group A, among the 38 non-converters, 12 reverted from MBI to their baseline functioning, 7 
were diagnosed with a late-onset primary psychiatric disorders and 19 remained stable.  
In group B among the 44 non-converters, 10 reverted to their baseline functioning, 8 were 




In this retrospective study, we evaluated which clinical characteristics and conventional MRI 
features were associated with the risk of conversion from MBI to dementia over time.  
Overall, we found that the presence of an executive deficit, severe theory of mind impairment and 
the presence of isolated frontal atrophy (i.e. with a spared volume within the remaining cortical 
regions) were associated with a higher risk of progression from MBI to a clinically evident 
neurodegenerative condition over the following 4 years. 
The diagnosis of MBI, similar to the usefulness of an MCI diagnosis, represents a good initial 
screening in order to identify patients most at risk for converting to one of the FTD-spectrum 
disorders over the following four years. Indeed, the development of new behavioural symptoms is a 
source of concern, especially for caregivers, and thus often leads to prompt clinical evaluations in a 
psychiatric or neurological setting 
30
. Moreover, population studies suggest that subjects with MBI 
are at higher risk to convert to a FTD-related disorder than those presenting with other constructs 
such as amnestic MCI
9
 
         
We found a higher risk of conversion from MBI to bv-FTD than to AD. This finding is not 
unexpected, given the previous observations of an involvement of behavioural changes in the 
earliest phases of bv-FTD
27,31
. Our results suggest that identifying MBI in the general population 
would help identify patients who would later present with bv-FTD.  
Like MCI, MBI is a relatively heterogeneous construct, and also includes subjects who will not 
progress to dementia. Thus, the identification of features able to dissect the MBI construct in order 
to distinguish who will develop dementia and what type of dementia would be useful. A first issue 
is represented by the concomitant presence of cognitive deficits. The presence of subjective 
cognitive complaints is an exclusion criteria for MBI
9
, however the presence of objective cognitive 
deficits is not. Indeed, subjects with MBI have been shown to present with a more marked cognitive 
decline over time compared to those without MBI
32
. Against this background, our data suggest that 
isolated executive and mentalizing deficits could allow clinicians to discriminate among MBI 
subjects those at risk to develop an underlying neurodegenerative condition.  
ToM is the ability to recognize emotions and inner states in others
16
. It is often involved in 
neurodegenerative conditions including the earliest phases of FTD
27
). ToM is partly independent of 
executive functions
33
 and indeed subjects without executive function deficits can present with ToM 
difficulties. These observations are in line with our findings of reduced ToM abilities in MBI 
subjects with an underlying neurodegenerative condition. It must be noted that ToM is a 
heterogeneous construct only partly probed by RMET, and thus it is possible that other ToM tests 
could have yielded different results. The RMET, however, lacks a ceiling effect even in healthy 
subjects, thus making it an ideal test to be included in a first level battery. 
Overall, our observation of an association between the presence of cognitive deficits and the risk of 
progression from MBI to dementia, is in keeping with the findings in MCI, where the involvement 
of multiple cognitive domains is associated with a worse prognosis
34
 as well as with the observed 




Furthermore, our data suggest that evidence of neurodegeneration at MRI (evaluated with simple 
scales) can be useful to evaluate the risk of conversion from MBI to bv-FTD, similar to what has 
been observed in MCI
36
. In the MBI setting, moreover, the identification of an FTD-related atrophy 
pattern, presents an added value, i.e. its differentiation with late-onset psychiatric conditions, as 
those are often associated only with specific MRI findings
37
. 
In agreement with these results, our data shows that specific and isolated frontal atrophy rather than 
global atrophy represents an easy-to-use marker to identify those MBI subjects more at risk to 
present a clinical conversion to bv-FTD. This is in keeping with the current inclusion of focal 
frontal atrophy in the diagnostic criteria for probable bv-FTD
28
. 
While the low number of incident dementia cases prompts caution in the interpretation of 
sensitivity, specificity and accuracy in our sample, the observed data suggests that the combination 
of cognitive/behavioural features and a simple assessment of brain atrophy at MRI could be useful 
to identify those MBI subjects more at risk to develop dementia. The increase in accuracy thanks to 
the combination of cognitive/behavioural data with structural MRI is in agreement with what is 
observed in MCI
38
, including diagnostic accuracy. The improvement in specificity due to the 
addition of an atrophy measure to the cognitive evaluation stems from the presence of executive and 
mentalizing deficits in subjects with late-onset psychiatric conditions – a common differential 
diagnosis of MBI – that however usually do not present with a specific brain atrophy pattern 
39
.  
While selection of the metrics included in the Cognitive-Behavioral index were based on the 
findings in Group A, they are in line with the known neuropsychological profile of FTD
40
, with a 
         
relative sparing of memory an involvement of social cognition and executive functions. As shown 
in the analysis of the sensitivity and specificity of each component of the Cognitive-Behavioral 
index, the focus on a “neuropsychological pattern” rather than a single test allowed to increase the 
specificity of the proposed approach, allowing to better differentiate FTD from - for example - late-
onset mood disorders that can present with an isolated ToM deficit
41
. Moreover, the combination of 
multiple tests to quantify the extent of the executive deficit allowed us to take into account the 
heterogeneity of the early cognitive deficits in FTD (i.e. the fact that in the earliest phases of 
bvFTD, patients can present with a pathological performance only in a single facet of executive 
functioning
42
). Indeed, the fact that the components of the indices probe different constructs is also 
confirmed by the moderate correlations between them.   
Thus, we decided to propose a set of indices (see Table 2) that may easily been followed to confirm 
the MBI conversion. Since the specificity of the cognitive and behavioural components is higher 
taken together rather than one by one, we decided to consider this aspect as a single index. Taking 
into account the single components of the Cognitive-Behavioral index, ToM task was the test 
presenting with the higher sensitivity. This suggest the importance of adding a formal evaluation of 
social cognition during neuropsychological assessment and it is in line with previous studies 
pointing to an early involvement of ToM in FTD
27
. 
Caution is needed in the clinical translation of our findings due to the retrospective nature of the 
study and our strict inclusion criteria. Thus, further, prospective, naturalistic studies are needed to 
confirm our findings. Moreover, the retrospective nature of the study did not allow us to collect data 
regarding caregiver burden.  
Despite these limitations, our four-year follow-up, detailed cognitive and behavioural data, and 
systematically-assessed structural imaging scans gives us confidence in the clinical utility of our 
results and increases our understanding of the heterogeneity of patients fulfilling MBI diagnostic 
criteria. 
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Table 1: Tarangano et al. (2003) MBI criteria 
1. Persistent behavioral changes and mild psychiatric symptoms, especially disinhibition 
2. No serious memory complaints 
3. Normal activities of daily living 
4. Absence of dementia 
 
 
Table 2: Indices of MBI conversion  
Cognitive-Behavioral 
- Executive functions z score < -1 
- RMET score < 21 
- Memory function z score > -1 
MRI 
- Isolated frontal atrophy  
 
  
         
Table 3: Demographic and clinical results in Group A. (df=degrees of freedom; bv-FTD=Behavioural Variant-Frontotemporal Dementia; AD=Alzheimer’s Disease; ToM=Theory 









































N (56) 38 18 14 
 
       
Age (m±sd) 65.4±7.9 64.5±6.3 63.9±8.5 p=0.673 
t= 
0.423 





Sex (m/f) 22/16 11/7 8/6 p=0.9   p=0.9 p=0.9   p=0.946 
T-test 
           
MMSE (m±sd) 28.4±2.3 28.0±3.4 28.2±2.9 p=0.606  
t= 
0.518   





ToM (m±sd) 0.4±1.0 -1.2±0.9 -1.2±0.6 p<0.001(p=0.008)





Executive functions score (m±sd) 0.3±0.6 -1.5±0.8 -1.9±0.4 p<0.001(p=0.008)
a t=9.397 d=2.54 p=0.002 p<0.001(p=0.008)a t=12.67 d=4.31 
p=0.002 
NPI (m±sd) 5.3±2.6 8.2±2.0 9.3±2.8 p=0.001(p=0.004)
b t=5.175 d=1.57 p=0.002 p<0.001(p=0.003)b t=4.821 d=1.48 p=0.002 
Memory score (m±sd) 0.1±0.8 -0.2±1.2 -0.1±0.8 p=0.270 
t= 
1.110 
d=0.29 p=0.510 p=0.423 t=0.799 d=0.25 
p=0.930 
         
 
Chi-square 
           
Isolated frontal atrophy (yes/no) 2/36 14/4 12/2 p<0.001(p=0.006)
c   p=0.002 p<0.001(p=0.005)c   p=0.002 
Isolated MTL atrophy (yes/no) 4/34 1/17 1/13 p=0.556   p= 0.756 p=0.784   p= 0.946 
Global atrophy (yes/no) 3/36 2/15 1/13 p=0.623   p= 0.756 p=0.946   p= 0.946 
WM load (Fazekas scale; m±sd) 1.2±0.4 1.4±0.3 1.2±0.5 p=0.065 t=1.881 d=0.56 p= 0.138 p=0.9 t=0 d=0 p= 0.946 
a=ancova with MMSE, NPI age and education; b=ancova with MMSE, age and education; c=logistic regression with MMSE, NPI, age and education (Wald chi-square (df = 1)) 
*based on all 17 tests reported in Table 3 and 4 . The same tests were used also for Bonferroni’s correction for multiple comparisons. 
         
Table 4: Demographic and clinical results in Group B (df=degrees of freedom; FTD=Frontotemporal Dementia; Cog-
Behav=Cognitive-Behavioura; n.s=not significantl)  
a=logistic regression with MMSE, NPI, age and education (Wald chi-square (df = 1))  








Converters vs. non-converters 
uncorrected p value 
T value 





N (57) 44 13    
Age 66.6±6.4 65.3±6.2 p=0.519 t=0.647 p= 0.756 
Sex (m/f) 23/21 7/6 p=0.9  p= 0.9 
MMSE (m±sd) 28.0±1.4 27.5±3.0 p=0.400 t=0.847 p= 0.68 
Chi-squared 
     
MRI criterion 
(fullfilled/not fulfilled) 
3/41 10/3 p<0.001(p=0.006)a  p=0.002 
Cog-Behav criterion 
(fullfilled/not fulfilled) 




0/44 8/5 p<0.001(p=0.006)a  p=0.002 
         
